Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Immutep Limited

News headline image
Immutep Announces Update for TACTI-004 (KEYNOTE-F91) Phase III Trial in First Line Non-Small Cell Lung Cancer
From Immutep Limited
Via GlobeNewswire
Tickers ASX:IMM IMMP
News headline image
Immutep’s Efti with KEYTRUDA® (pembrolizumab) & Chemotherapy Achieves High Response Rates in First-Line Non-Small Cell Lung Cancer
From Immutep Limited
Via GlobeNewswire
Tickers ASX:IMM IMMP
News headline image
Immutep’s Efti Shows Excellent Survival Data from INSIGHT-003 Trial in Non-Small Cell Lung Cancer
From Immutep Limited
Via GlobeNewswire
Tickers ASX:IMM IMMP
News headline image
Immutep Announces Positive Preliminary Topline Results from TACTI-003 Cohort B
From Immutep Limited
Via GlobeNewswire
Tickers ASX:IMM IMMP
News headline image
Immutep Reports Promising Clinical Data from INSIGHT-003 Trial at ESMO Congress 2023
From Immutep Limited
Via GlobeNewswire
Tickers ASX:IMM IMMP
News headline image
Immutep’s Efti in Combination with KEYTRUDA® Generates Excellent Overall Survival Benefit in Patients with Metastatic Non-Small Cell Lung Cancer
From Immutep Limited
Via GlobeNewswire
Tickers ASX:IMM IMMP
News headline image
Immutep’s Efti in Combination with Pembrolizumab Achieves Excellent Initial Overall Survival Benefit in 1st Line Non-Small Cell Lung Cancer
From Immutep Limited
Via GlobeNewswire
Tickers ASX:IMM IMMP
News headline image
Immutep Receives Approval to Initiate INSIGHT-005 Trial Evaluating Eftilagimod Alpha and Anti-PD-L1 Therapy BAVENCIO®
From Immutep Limited
Via GlobeNewswire
Tickers ASX:IMM IMMP
News headline image
Immutep Enters into Second Clinical Trial Collaboration Agreement with Merck KGaA, Darmstadt, Germany, and Pfizer for New Combination Study of its First-in-Class LAG-3 Candidate, Eftilagimod Alpha, and Avelumab to Treat Urothelial Cancer
From Immutep Limited
Via GlobeNewswire
Tickers ASX:IMM IMMP
News headline image
Immutep Granted New Patents in Japan and South Korea for First-in-Class LAG-3 Candidate, Eftilagimod Alpha in Chemo-Immunotherapy Combination
From Immutep Limited
Via GlobeNewswire
Tickers ASX:IMM IMMP
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.